[Pharmacokinetic studies after oral and parenteral application of dipotassium chlorazepate (author's transl)].
Pharmacokinetic investigations after oral and intravenous application of 50 mg and 100 mg 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carbonic acid (dipotassium clorazepate, DPC, Tranxilium, Tranxène) were conducted with two groups of male subjects (A: N = 7; B: N = 6). DPC and its metabolites, nordiazepam (ND) and oxazepam (OX), were measured in blood and urine. After oral application of DPC the expected metabolite pattern was observed. But after i.v. infection of 50 mg or 100 mg DPC a rapid increase of DPC- and also ND-concentrations in the serum was shown. The pattern of the metabolites excreted in urine differed considerably between the groups with oral and i.v. administration of DPC. The possible causes of rapid biotransformation in the serum are discussed.
D000284:Administration, Oral; D000328:Adult; D014151:Anti-Anxiety Agents / Q000378:metabolism*; D003009:Clorazepate Dipotassium / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D010076:Oxazepam / Q000378:metabolism
D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium; D010076:Oxazepam
Pharmakokinetische Untersuchungen nach oraler und parenteraler Applikation von Dikalium-chlorazepat.